A Validation Study of the Neuro-cognitive Emotion Monitoring-Intervention (NEMO-I) Application in Adolescents
NCT07700264, Not applicable, Not yet recruiting, Seoul Women's University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | A Validation Study of the Neuro-cognitive Emotion Monitoring-Intervention (NEMO-I) Application in Adolescents | ClinicalTrials.gov |
| NCT number | NCT07700264 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 140 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Seoul Women's University | ClinicalTrials.gov |
| Conditions | Adolescent Mental Health, Adolescent - Emotional Problem, Cognition Improvement | ClinicalTrials.gov |
| Interventions | NEMO-I (Neuro-cognitive Emotion Monitoring-Intervention) | ClinicalTrials.gov |
| First posted | 2026-07-14 | ClinicalTrials.gov |
| Last updated | 2026-07-14 | ClinicalTrials.gov |
Registered outcomes 13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in depressive symptoms | Baseline (pre-intervention) and after the 21-day intervention period | Depressive symptoms are measured using the Beck Depression Inventory-II (BDI-II), a 21-item self-report questionnaire. Total scores range from 0 to 63, with higher scores indicating more severe depressive symptoms. Change is assessed by comparing pre- and post-intervention scores. | ClinicalTrials.gov |
| Primary | Change in inhibitory control (Color-Word Stroop Test, CWST) | Baseline(pre-intervention) and after the 21-day intervention period | Inhibitory control is assessed using the Color-Word Stroop Test (CWST), which measures the efficiency of the frontal-lobe inhibition process. Performance is indexed by response time and error rate under the color-word interference condition. Change is assessed by comparing pre- and post-intervention performance. | ClinicalTrials.gov |
| Primary | Change in anxiety symptoms | Baseline(pre-intervention) and after the 21-day intervention period | Anxiety symptoms are measured using the Beck Anxiety Inventory (BAI), a 21-item self-report questionnaire assessing the severity of anxiety-related symptoms. Higher scores indicate greater anxiety. Change is assessed by comparing pre- and post-intervention scores. | ClinicalTrials.gov |
| Primary | Change in neuro-cognitive and emotional function (NEMO-A) | Baseline (pre-intervention) and after the 21-day intervention period | Neuro-cognitive and emotional function is assessed using the NEMO-A (Neuro-cognitive Emotion Monitoring-Assessment) application, a tablet-based, game-format assessment consisting of five subtasks. It measures domains including sustained attention, working memory, emotional sensitivity, emotion processing and recognition, audiovisual emotional integration, cognitive control, and executive function. Performance is indexed by accuracy and response time, and change is assessed by comparing pre- and post-intervention performance. | ClinicalTrials.gov |
| Primary | Change in visual attention and processing speed (Children's Color Trails Test, CCTT) | Baseline (pre-intervention) and after the 21-day intervention period | Visual attention, psychomotor speed, sequential processing, and divided/sustained visual attention are assessed using the Children's Color Trails Test (CCTT). Performance is indexed by completion time (seconds). Change is assessed by comparing pre- and post-intervention performance. | ClinicalTrials.gov |
| Primary | Change in set-shifting ability (Trail Making Test-B, TMT-B) | Baseline (pre-intervention) and after the 21-day intervention period | Set-shifting ability and cognitive flexibility are assessed using the Trail Making Test-B (TMT-B), which requires alternating between numbers and letters in sequence. Performance is indexed by completion time (seconds). Change is assessed by comparing pre- and post-intervention performance. | ClinicalTrials.gov |
| Secondary | Change in subjective stress | Baseline (pre-intervention) and after the 21-day intervention period | Subjective stress is measured using a Visual Analog Scale (VAS), on which participants rate their current perceived stress level from 1 (no stress) to 10 (extreme stress). | ClinicalTrials.gov |
| Secondary | Change in daily stress | Baseline(pre-intervention) and after the 21-day intervention period | Daily stress is measured using a 26-item self-report scale assessing stress experienced in everyday domains such as parents, school, academics, peer relationships, appearance, and finances, rated on a 5-point Likert scale. | ClinicalTrials.gov |
| Secondary | Change in alexithymia | Baseline (pre-intervention) and after the 21-day intervention period | Difficulty identifying and describing one's own emotions is measured using the Korean version of the 20-item Toronto Alexithymia Scale (TAS-20K), rated on a 5-point Likert scale. | ClinicalTrials.gov |
| Secondary | Change in executive function difficulties (self-report) | Baseline (pre-intervention) and after the 21-day intervention period | Self-reported executive function difficulties are measured using the Brief Self-Report Questionnaire of Executive Function Difficulty for children and adolescents (40 items), rated on a 3-point Likert scale. | ClinicalTrials.gov |
| Secondary | Change in peer relationship quality | Baseline (pre-intervention) and after the 21-day intervention period | The quality of peer relationships is measured using a 13-item self-report scale rated on a 4-point Likert scale, including items reflecting conflict and negative peer interactions. | ClinicalTrials.gov |
| Secondary | Change in problem behaviors (CBCL 6-18, parent report) | Baseline (pre-intervention) and after the 21-day intervention period | Problem behaviors are assessed using the Child Behavior Checklist for Ages 6-18 (CBCL 6-18), completed by a parent or primary caregiver. It includes internalizing problems (e.g., anxiety, depression, somatic complaints) and externalizing problems (e.g., rule-breaking, aggressive behavior). | ClinicalTrials.gov |
| Secondary | Change in ADHD symptoms (ARS, parent report) | Baseline (pre-intervention) and after the 21-day intervention period | Attention-deficit/hyperactivity symptoms are assessed using the ADHD Rating Scale (ARS), an 18-item parent-report questionnaire comprising inattention and hyperactivity/impulsivity subscales. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 2
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Trail Making Test B | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)